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Somatic GNAS point mutations, commonly known as gsp mutations, are involved in the 
pathogenesis of McCune–Albright syndrome (MAS) and have also been described in 
autonomous hormone-producing tumors, such as somatotropinoma, corticotrophoma, 
thyroid cancer, ovarian and testicular Leydig cell tumors, and primary macronodular 
adrenocortical hyperplasia (PMAH) (1–3). The involvement of gsp mutations in adrenal 
tumors was first described by Lyons et al. Since then, several studies have detected the 
presence of gsp mutations in adrenal tumors, but none of them could explain its presence 
along or the mechanism that leads to tumor formation and hormone hypersecretion. As 
a result, the molecular pathogenesis of the majority of sporadic adrenocortical tumors 
remains unclear (3). PMAH has also been reported with gsp somatic mutations in a few 
cases. Fragoso et  al. identified two distinct gsp somatic mutations affecting arginine 
residues on codon 201 of GNAS in a few patients with PMAH who lacked any features 
or manifestations of MAS. Followed by this discovery, other studies have continued 
looking for gsp mutations based on strong prior evidence demonstrating that increased 
cAMP signaling is sufficient for cell proliferation and cortisol production (2, 4). With 
consideration for the previously reported findings, we conjecture that although somatic 
activating mutations in GNAS are a rare molecular event, these mutations could probably 
be sufficient to induce the development of macronodule hyperplasia and variable cortisol 
secretion. In this manuscript, we revised the presence of gsp mutations associated with 
adrenal cortical tumors and hyperplasia.
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inTRODUCTiOn
Heterotrimeric G proteins are the molecular switches that turn on intracellular signaling cascades 
in response to the activation of G protein-coupled receptors (GPCRs) by extracellular stimuli. 
Therefore, G proteins play a crucial role in defining the specificity and temporal characteristics of 
the cellular response. Heterotrimeric G proteins consist of three subunits, α, β, and γ, and their 
switching function depends on the ability of the G protein α-subunit (Gα) to cycle between an 
inactive GDP-bound conformation that is primed to interact with an activated receptor and an active 
GTP-bound conformation that can modulate the activity of downstream effector proteins. The α 
subunit is a GTPase; therefore, when the receptor stimulates the G protein, this subunit releases GDP 
FiGURe 1 | Schematic representation of cAMP pathway. GPCRs cause the activation of G proteins by facilitating the exchange of GTP for GDP on the α 
subunit. cAMP is degraded to AMP by PDEs. PKA is activated by the rise in cAMP that, by binding both high-affinity cAMP-binding sites of each subunit, leads 
to the release of active subunits that phosphorylate their substrates, including the nuclear transcription factor, CREB. By inhibiting the intrinsic GTPase activity, 
gsp mutations cause constitutive activation of adenylyl cyclase (AC), leading to increased cAMP; protein kinase A activation. The protein kinase A (PKA) 
induces phosphorylation of the cAMP-binding protein, CREB, facilitating its traslocation to the nucleus and activation of cAMP-responsive gene transcription. 
[Adapted from Lacroix et al. (11)].
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and binds GTP. In this activated state, several α subunit types act 
directly on effector molecules to modulate their activity. Some α 
subunits show specificity for effectors; for example, αs activates 
adenylate cyclases, αi inhibits adenylate cyclases, and αq activates 
phospholipase C isozymes (5) (Figure 1).
The gene encoding the alpha subunit of stimulatory G proteins 
(GNAS, OMIM 139320) is located on chromosome 20q13.32 (6). 
Activating somatic mutations of stimulatory G protein called gsp 
mutations can result in the loss of intrinsic GTPase activity of 
the α subunit with subsequent constitutive activation of adenylate 
cyclase (7, 8).
gsp mutations are involved in the pathogenesis of McCune–
Albright syndrome (MAS), which is an endocrine disorder that is 
classically defined by the clinical triad of bone fibrous dysplasia, 
café-au-lait skin, and peripheral precocious puberty (1).
Patients with MAS present with a postzygotic gsp mutation 
in a mosaic distribution, resulting in varying degrees of tissue 
involvement that range from a single site to a widespread distri-
bution. However, if these mutations were germline, they would 
be lethal. To date, this concept is supported by the absence of any 
cases resulting from vertical transmission and the discordance in 
disease among monozygotic twins (9). Adrenal hypercortisolism 
affects a minority of patients with MAS due to adrenal nodular 
hyperplasia and around 20 cases were described (8).
Naturally occurring mutations in codons 201 and 227, 
which  alter the GTPase activity in the GNAS gene, have 
been described in autonomous hormone-producing tumors. 
Mutations involving substitution of either cysteine or histidine 
and, more rarely, serine for arginine at codon 201 or arginine for 
glutamine at codon 227 were first described in GH-producing 
pituitary tumors (10).
The gsp mutations have also been described in several tumors, 
such as somatotropinoma, thyroid tumor, ovarian and testicular 
Leydig cell tumors, and primary macronodular adrenocortical 
hyperplasia (PMAH), as well as in rare cases of corticotropinoma, 
cortisol, and aldosterone-secreting adrenocortical adenoma. 
All cases described were outside of the classical presentation of 
MAS (1, 2, 4, 7).
cAMP/PKA Signaling in 
Adrenocortical Cells
The discovery of the role of cAMP (adenosine 3′5′-cyclic 
monophosphate) as an intracellular mediator introduced the 
concept of second messengers in signal transduction. cAMP is 
a nucleotide synthesized within cells using ATP, and it is under 
the action of a membrane-bound enzyme, adenylate cyclase. 
cAMP is continuously produced and inactivated by hydrolysis 
FiGURe 2 | Schematic representation of G protein activation and signaling. Heterotrimeric G proteins are composed of three distinct subunits alpha, beta, 
and gamma. Activity G protein depends on the alpha subunit. The alpha subunit contains high-affinity binding sites for guanine nucleotides (GDP) and has intrinsic 
GTPase activity. The GDP-bound form binds tightly to beta and gamma units in its inactive state. The GTP-bound form dissociates from beta and gamma units and 
serves as a regulator of effectors proteins. The receptor molecules cause the activation of G proteins by facilitating the exchange of GTP for GDP on the alpha 
subunit. The duration of subunit separation is timed by the rate of alpha subunit-mediated hydrolysis of GTP. The gsp mutations Arg201Cys and Gln227Arg at 
exons 8 and 9, respectively, of GNAS causing a constitutive signal of cAMP pathway.
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of 5′-AMP through a family of enzymes known as phosphodi-
esterase (12–14).
cAMP regulates many aspects of cell function, including 
enzymes involved in energy metabolism, cell division and dif-
ferentiation, ion transport, ion channels, and contractile proteins. 
However, these effects are produced by a common mechanism, 
the activation of protein kinases by cAMP (Figure 2).
Proteins are phosphorylated by various protein kinases. 
The substrates of protein kinases and phosphatases include 
enzymes, neurotransmitter receptors, ion channels, and 
structural proteins, activating or inhibiting through phospho-
rylation, the target enzymes or ion channels. The increased 
cAMP production in response to the activation of β-adrenergic 
receptors affects several enzymes that are involved in glycogen 
metabolism, adipocytes, and muscle cells. The result consists of 
a coordinated response in which the energy stored as glycogen 
and fat becomes available as glucose, acting as a supply for 
muscle contraction (15).
cAMP, a second messenger, and its effector, protein kinase 
A (PKA), are key regulators of practically all cellular functions, 
such as cell growth and cell differentiation, and proliferation, and 
they mediate the effects of several hormones and neurotransmit-
ters via GPCRs. This pathway is one of the major participants in 
the regulation of growth, proliferation, and hormonal secretion 
in adrenocortical cells (16, 17).
Once two cAMP molecules bind to each R subunit, the C 
subunits are released from the holoenzyme and can phospho-
rylate their targets, which are localized in the cytosol and in 
the nucleus. In adrenocortical cells, there is stimulation of 
glucocorticoid synthesis as well as transcriptional induction of 
steroidogenic enzymes and activation genes that are involved in 
cell replication (15, 18).
The majority of benign lesions of the adrenal cortex that lead 
to cortisol overproduction are linked to abnormalities of the 
cAMP pathway. Genetic defects in the cAMP/PKA that maintain 
pathway activation have been associated with adrenal disorders 
as follows:
(1) Ectopic expression of G protein-coupled receptors (19, 20).
(2) Somatic activating mutations in the gene coding for the Gαs 
protein (GNAS) (6, 10, 21).
(3) Somatic activating mutations in the corticotropin receptor 
gene, MC2R (22, 23).
(4) Germline and/or somatic inactivating mutations in the gene 
coding for the RIα subunit of PKA (PRKAR1A) (13, 14, 18).
(5) Inactivating germline mutations in the genes coding two 
phosphodiesterases (PDE8 and PDE11A) (24, 25).
(6) Activating germline mutations in the gene coding for the Cα 
subunit of PKA (PRKACA) (26).
(7) Somatic mutations in PRKACA, which encodes the catalytic 
subunit of cyclic AMP-dependent protein kinase (27).
(8) Germline and somatic inactivating mutations of ARMC5 
(28, 29).
Nevertheless, because these molecular events are not able to 
explain all cases of adrenocortical disorders, part of the molecular 
pathogenesis of the tumors causing Cushing’s syndrome remains 
a challenge to scientific researchers.
gsp Mutations in Adrenal Cortical Tumors
Somatic mutations of genes encoding components of the cAMP/
PKA pathway (GNAS, PRKAR1A, PDE8B) and β-catenin 
(CTNNB1) have been reported in a small subset of adrenocortical 
tumors that produce cortisol (27, 30).
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The first report of the involvement of gsp mutations in adrenal 
tumors was by Lyons et al. In this study, the group tested the gene 
that encodes the alpha chain of Gi2, and the authors detected 
mutations that replaced arginine-179 with either cysteine or histi-
dine in 3 of 11 tumors of the adrenal cortex and 3 of 10 endocrine 
tumors of the ovary (31).
Yoshimoto et al. systemically screened Gs alpha mutations in 
197 human endocrine tumors. They included pituitary, thyroid, 
parathyroid, endocrine pancreas, and (cortex and medulla) 
adrenal tumors. They identified a unique, 29-year-old female 
patient with primary aldosteronism associated with a somatic gsp 
mutation in an aldosterone-producing adrenocortical adenoma. 
The authors commented that when the renin–aldosterone 
system is suppressed, aldosterone-producing adrenal adenomas 
become more sensitive to corticotropin stimulation. In this way, 
corticotropin is transmitted via Gs alpha-mediated cyclic AMP 
production. The study hypothesized that the gsp mutations may 
constitutively stimulate aldosterone synthesis in the glomerulosa 
zone, transmitting a constitutive signal via Gs-mediated cyclic 
AMP production, which would play an important role in the 
tumorigenesis of the aldosterone-secreting adenoma (3).
In 2000, Bugalho et  al. described the presence of a muta-
tion at codon 201 (CGT to TGT) in a patient with Cushing’s 
syndrome due to a functioning adrenal adenoma (32). In 2004, 
Dall’Asta et al. also identified gsp mutations in one patient with 
ACTH-independent Cushing’s syndrome. The presence of the gsp 
mutation seemed to alter the cortisol responses to agents via Gs 
protein-coupled receptors, whereas these responses are absent in 
other cases of adenoma-producing Cushing’s syndrome without 
gsp mutations (33).
Moreover, Libé and Bertherat investigated the presence of 
genetic alterations on a series of 10 ACTH-independent Cushing’s 
syndrome cases due to adrenocortical cortisol-secreting adeno-
mas. The gsp mutation was identified in only one case, demon-
strating that this abnormality is a rare cause of adrenocortical 
tumors. These findings suggest that different mechanisms are 
probably involved in adrenal tumorigenesis in primarily benign 
disorders (34).
A study conducted by Almeida et al. using the whole-genome 
expression profile (WGEP) of PRKAR1A and GNAS-mutant 
analysis revealed that not all cAMP activation is the same. 
Adrenal lesions harboring PRKAR1A or GNAS mutations share 
downstream activation of specific oncogenic signals (such as 
MAPK and cell cycle genes), but they differ substantially in their 
effects on others. These results support the hypothesis that several 
pathways can activate cAMP (13).
In 2013, Sidhu et al. described, for the first time, the presence 
of the p.R201C, a GNAS activating mutation in a malignant 
pediatric adrenocortical tumor. The malignant features described 
were as follows: areas of necrosis, microcytic degeneration, and 
both venous and capsular microinvasion. The tumor tissue also 
presented with abnormal allele-specific hypomethylation of the 
KCNQ1OT1 gene involved in Beckwith–Wiedemann syndrome. 
Somatic mutations in these genes may constitutively activate the 
cAMP-protein kinase cascade, leading to cellular proliferation, 
which may then result in genomic instability and epigenetic altera-
tions that give rise to ACTs and malignancy. This study suggested, 
for the first time, that activation of the cAMP-PKA cascade alone 
may not be sufficient to cause malignant transformation in the 
adrenal cortex without resulting in secondary events (35).
Recently, somatic mutations of PRKACA (encoding the 
catalytic subunit of PKA) have been identified in more than 
one-third of the patients with Cushing’s syndrome from sporadic 
adrenocortical adenomas; however, the molecular pathogen-
esis of the majority of sporadic adrenocortical tumors remains 
unclear (18, 27, 36).
In summary, apart from the known somatic mutations 
described in the literature, no other recurrent mutation by itself 
can explain the mechanism of tumor formation and hormone 
hypersecretion.
gsp Mutations in Primary Macronodular 
Adrenal Hyperplasia
Over the last two decades, different studies have supported that 
multiple molecular mechanisms may be involved in the patho-
genesis of PMAH (7, 12–14, 37). Several pathways were studied 
and analyzed for gene alterations, suggesting that there may be a 
heterogeneous group of diseases with a common presentation, 
ranging from subclinical hypercortisolism to overt Cushing’s 
syndrome.
Bilateral adrenal hyperplasia may be part of MAS that is asso-
ciated with hypercortisolism, especially in young children during 
the first years of age. The adrenal nodules of these patients carried 
the gsp mutation and adrenal cortical cells increased the levels of 
cAMP (6, 8).
In 2003, Fragoso et  al. identified two distinct gsp somatic 
mutations affecting arginine residues in codon 201 of GNAS in a 
few patients with PMAH without any features or manifestations 
of MAS (2).
Subsequently, Hsiao et  al. also reported the presence of gsp 
somatic mutation in one additional patient with PMAH (4). On 
the other hand, an additional study failed to observe gsp muta-
tions in PMAH (37). Technical variations in the methodologies 
employed for the investigation of gsp mutations could explain the 
discrepancy in these published findings.
Almeida et al. described the analyzed the WGEP of primary 
pigmented nodular adrenocortical disease (PPNAD) patients 
associated with gsp mutations. The data indicated that cAMP 
activation in adrenal lesions harboring gsp mutations share the 
downstream activation of some oncogenic signals but differ 
significantly in their effects on others (13).
Considering the great variation of MAS, these cases 
might  characterize late gsp somatic mutations considering that 
similar mutations have been described outside the context of 
MAS (e.g.,  acromegaly, thyroid cancer, and ovarian–testicular 
 neoplasms) (7).
Based on strong previous evidence implying that increased 
cAMP signaling is sufficient for cell proliferation and cortisol 
production, we posit that although these somatic activating 
mutations in GNAS are a rare molecular event, they are probably 
sufficient to induce the development of macronodule hyperplasia 
and variable cortisol secretion (12, 38, 39).
Primary macronodular adrenocortical hyperplasia is a hetero-
geneous disorder that could be associated with genetic defects in 
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both germline and somatic levels. The presence of somatic gsp 
mutations was detected in rare cases with PMAH without MAS 
features. The role of gsp mutations in the development of this 
adrenal disorder remains partially unclear (2).
Recent studies have now indicated that PMAH is more fre-
quently genetically determined than previously believed (28, 29). 
Germline mutations of ARMC5 in ~50% of patients with appar-
ently sporadic PMAH, and also in a large family with genetically 
transmitted PMAH. The ARMC5 has no apparent link to the 
cAMP pathway, but its inactivation decreases the expression of 
both MC2R and various steroidogenic enzymes (19).
Activation of Cyclic AMP Signaling in 
Lesions of the Adrenal Cortex due to 
Somatic GnAS Mutations
Aberrations in cAMP/PKA signaling are essential to the patho-
genesis of benign cortisol-producing lesions of the adrenal 
cortex (40).
An important study by Almeida and coauthors analyzed the 
WGEP of adrenal lesions harboring somatic GNAS mutations 
in the normal adrenal pool and tissue with somatic PRKAR1A 
genes. They included three microdissected samples from adrenal 
lesions that were all caused by the same somatic GNAS muta-
tion (p.R201H) as follows: a cortisol-producing adenoma from 
patients with PMAH and Cushing’s syndrome and hyperplasia 
from patients with MAS and Cushing’s syndrome. The results of 
this study showed that the MAPK and p53 signaling pathways 
were highly overexpressed in all lesions compared with normal 
tissues. GNAS-mutant tissues were significantly enriched for 
extracellular matrix receptor interaction and focal adhesion 
pathways compared with PRKAR1A mutants. In addition, NFKB, 
NFKBIA, and TNFRSF1A were overexpressed in GNAS-mutant 
adrenal tissue (13).
NFKB is a transcription activator nuclear factor kappa 
light-chain enhancer of activated B cells, a complex protein 
that controls DNA transcription, cytokine production, and 
cell survival. The nuclear factor kappa–beta controls the 
expression of various genes that are involved in cancer-related 
processes, including immune and inflammatory responses; 
cell adhesion, proliferation, differentiation, and apoptosis; and 
angiogenesis (13).
TNFRSF1A is a tumor necrosis factor receptor member of the 
superfamily 1A and the protein encoded by this gene is a member 
of the TNF-receptor superfamily. This protein is one of the major 
receptors for tumor necrosis factor-alpha. This receptor can 
activate NF-kappa–beta and mediate apoptosis, and it functions 
as a regulator of inflammation (13).
The study of adrenal lesions harboring PRKAR1A or GNAS 
mutations, conducted by Almeida et  al. suggested that cAMP 
signaling inhibitors could be used as molecularly designed 
therapies for subclinical CS in the context of bilateral adrenal 
hyperplasia (13).
Despite the importance of the cAMP pathway, these molecular 
events are a rare cause of adrenocortical tumors and adrenal 
hyperplasia, showing that several other genes should be involved 
in the cAMP pathway as long as other genes are involved in 
adrenal tumorigenesis and hyperplastic development.
new inSiGHTS
This review aimed to provide a summary of the main studies 
on the role of cAMP and gsp mutations on the development of 
adrenocortical tumors and adrenal hyperplasia. Throughout this 
review, we showed that gsp mutations are a rare cause of adrenal 
disorders and involvement of gsp mutations in increasing the 
cAMP levels is not always detected.
The molecular pathogenesis of cortisol-producing adrenal 
adenomas and adrenal hyperplasia is not well understood.
Somatic mutations in the gene encoding beta-catenin 
(CTNNB1) have primarily been found in non-secreting adreno-
cortical adenomas, and there is some evidence that increased 
endocrine activity may be linked to aberrant cAMP signaling.
Tumor suppressor genes point mutations (such as CTNNB1) 
and alterations in the cortisol producing (ARMC5 and PKC muta-
tions) could lead to alterations in cAMP pathway.
Mutations in the genes PDE11A, PDE8B, and PRKAR1A have 
also been identified in patients with adrenal disorders related to 
cortisol production (14).
Nevertheless, lesions of the adrenal gland that are associated 
with adrenal Cushing syndrome, independent of their GNAS, 
PRKAR1A, PDE11A, and PDE8B mutations, have functional 
abnormalities in cAMP signaling. It is hypothesized that epi-
genetic events or additional genetic defects of the regulatory 
molecules in this pathway exist and have yet to be identified (41).
COnCLUSiOn
The genetic analyses of the molecular pathogenesis of sporadic 
cortisol-secreting adrenocortical adenomas confirm the key role 
of the cAMP/PKA-signaling pathway in stimulating both the 
function and proliferation of adrenocortical cells. They provide 
insights into the development of adrenal hormonal autonomy 
and may provide the basis for novel advances in the diagnosis 
and therapy of adrenal Cushing’s syndrome.
In conclusion, this review demonstrates that not all increased 
cAMP/PKA signaling has the same effect on adrenocortical 
tumor formation. The role of non-PKA-dependent func-
tions of cAMP in the adrenal cortex has not been adequately 
investigated.
Based on strong previous evidence implying that increased 
cAMP signaling is sufficient for cell proliferation and cortisol 
production (38), we surmise that although really rare, these gsp 
mutations are probably sufficient for macronodule formation and 
the hypercortisolism status.
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